{"organizations": [], "uuid": "ffebafbad60ff108ab442d1e67a55b61447bbfd6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-karyopharm-therapeutics-reports-q4/brief-karyopharm-therapeutics-reports-q4-loss-per-share-of-0-80-idUSASC09SDX", "country": "US", "domain_rank": 408, "title": "BRIEF-Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-15T13:18:00.000+02:00", "replies_count": 0, "uuid": "ffebafbad60ff108ab442d1e67a55b61447bbfd6"}, "author": "", "url": "https://www.reuters.com/article/brief-karyopharm-therapeutics-reports-q4/brief-karyopharm-therapeutics-reports-q4-loss-per-share-of-0-80-idUSASC09SDX", "ord_in_thread": 0, "title": "BRIEF-Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "dec", "sentiment": "none"}, {"name": "karyopharm therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 15, 2018 / 11:20 AM / Updated 5 minutes ago BRIEF-Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80 Reuters Staff March 15 (Reuters) - Karyopharm Therapeutics Inc: * KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS * Q4 LOSS PER SHARE $0.80 * Q4 EARNINGS PER SHARE VIEW $-0.65 â€” THOMSON REUTERS I/B/E/S * PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MYELOMA REMAINS ON TRACK * TOP-LINE DATA FROM PHASE 2B STORM STUDY EXPECTED END OF APRIL 2018 * KARYOPHARM - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, INCLUDING RESTRICTED CASH, TOTALED $176.4 MILLION, VERSUS $175.5 MILLION AT DEC 31, 2016 * EXPECTS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q1 2019 * QTRLY LICENSE AND OTHER REVENUE $1.5 MILLION VERSUS $ 47,000 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-03-15T13:18:00.000+02:00", "crawled": "2018-03-15T13:38:51.016+02:00", "highlightTitle": ""}